Background-Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting. Ticagrelor, a reversible oral P2Y12-receptor antagonist, provides faster, greater, and more consistent platelet inhibition than clopidogrel and may be useful for patients with acute ST-segment elevation (STE) ACS and planned primary percutaneous coronary intervention. Methods and Result-Platelet Inhibition and Patient Outcomes (PLATO), a randomized, double-blind trial, compared ticagrelor with clopidogrel for the prevention of vascular events in 18 624 ACS patients. This report concerns the 7544 ACS patients with STE or left bundle-branch block allocated to either ticagrelor 180-mg loading dose followed by 90 mg twice daily or clopidogrel 300-mg loading dose (with provision for 300 mg clopidogrel at percutaneous coronary intervention) followed by 75 mg daily for 6 to 12 months. The reduction of the primary end point (myocardial infarction, stroke, or cardiovascular death) with ticagrelor versus clopidogrel (10.8% versus 9.4%; hazard ratio [HR], 0.87; 95% confidence interval, 0.75 to 1.01; Pϭ0.07) was consistent with the overall PLATO results. There was no interaction between presentation with STE/left bundle-branch block and randomized treatment (interaction Pϭ0.29). Ticagrelor reduced several secondary end points, including myocardial infarction alone (HR, 0.80; Pϭ0.03), total mortality (HR, 0.82; Pϭ0.05), and definite stent thrombosis (HR, 0.66; Pϭ0.03). The risk of stroke, low in both groups, was higher with ticagrelor (1.7% versus 1.0%; HR,1.63; 95% confidence interval, 1.07 to 2.48; Pϭ0.02). Ticagrelor did not affect major bleeding (HR, 0.98; Pϭ0.76). Conclusion-In patients with STE-ACS and planned primary percutaneous coronary intervention, the effects of ticagrelor were consistent with those observed in the overall PLATO trial. Clinical Trial Registration-URL: http://www.ClinicalTrials.gov. Unique identifier: NCT00391872. (Circulation. 2010;122:2131-2141.) Key Words: acute coronary syndrome Ⅲ hemorrhage Ⅲ myocardial infarction Ⅲ platelets Ⅲ thrombosis R apid, consistent, and pronounced P2Y12 inhibition is important for treatment of patients with acute coronary syndrome (ACS), particularly in ST-segment elevation ACS (STE-ACS), and in patients treated with intracoronary stent and is recommended in these patients for up to 1 year after the index episode. 1,2 Clopidogrel yields moderate and variable inhibition of platelet aggregation with a fairly slow onset, even with the currently recommended double loading dose. 3 These variations have been shown to affect clinical outcomes in ACS, 4 -8 particularly in patients undergoing primary percutaneous coronary intervention (PCI) for STE-ACS. 9 Furthermore, the addition of clopidogrel to aspirin is associated
with an increased risk of bleeding, especially in patients undergoing invasive procedures 10 or coronary surgery. 11 
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Ticagrelor, the first reversibly binding oral P2Y12 receptor antagonist, provides faster, greater, and more consistent inhibition of platelet aggregation than clopidogrel. [12] [13] [14] [15] Ticagrelor was compared with clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial 16 in a broad population of patients with either non-STE-ACS, regardless of the intended management strategy (ie, medical, interventional, or surgical), or STE-ACS with planned primary PCI. PLATO demonstrated that treatment with ticagrelor instead of clopidogrel reduced the risk of death resulting from vascular causes, myocardial infarction (MI), or stroke during 12 months without increasing the overall risk of major bleeding. There were also reductions in cardiovascular and total mortality, MI, and stent thrombosis with ticagrelor. 17 Patients with STE-ACS and planned primary PCI require particularly urgent and effective blockade of the P2Y12 receptor yet also represent a group potentially at greater risk of side effects from new therapies. The objective of the present predefined subgroup analysis of the PLATO trial was to examine the efficacy and safety of ticagrelor compared with clopidogrel in patients with STE-ACS intended for reperfusion with primary PCI.
Methods
Design PLATO (http://www.ClinicalTrials.gov No. NCT00391872) was an international, prospective, randomized, double-blind, doubledummy, event-driven trial in patients hospitalized for acute STE-ACS and scheduled for a primary PCI strategy or non-STE-ACS that was managed invasively or medically. Details of the design, population, and outcome measures have been published. 16, 17 Patients were randomized to receive either ticagrelor or clopidogrel within 24 hours of onset of the most recent cardiac ischemic symptoms and before PCI. Ticagrelor-treated patients received a 180-mg loading dose followed by a maintenance dose of 90 mg BID. Clopidogreltreated patients who had not already received a loading dose of open-label clopidogrel or who had not been taking clopidogrel or ticlopidine for Ն5 days before randomization received a 300-mg loading dose followed by 75 mg QD. The remaining patients received 75 mg clopidogrel as their first dose. Patients undergoing PCI received an additional 90-mg dose of ticagrelor/placebo at procedures Ͼ24 hours after randomization and, at the discretion of the investigator, an additional 300 mg clopidogrel/placebo at any time relative to randomization. All patients received 75 to 100 mg/d acetylsalicylic acid unless intolerant. For patients not previously receiving acetylsalicylic acid, a loading dose of 325 mg was preferred (although a dose of 160 to 500 mg was allowed). After stent placement, an acetylsalicylic acid dose up to 325 mg/d was allowed for up to 6 months, 18 and a lower dose was used thereafter. Outpatient visits were scheduled up to 12 months, with a safety follow-up visit 1 month after the end of treatment. The randomized treatment was scheduled to continue for 12 months, but patients left the study at their 6-or 9-month visit if the targeted number of 1780 primary end-point events had occurred by that time. It was recommended that study drugs be withheld in patients undergoing coronary artery bypass graft (CABG), 5 days for clopidogrel study drug and 24 to 72 hours for ticagrelor study drug, while maintaining the study blind.
Patients
This analysis addresses the subgroup of patients with STE-ACS, defined as typical symptoms plus either persistent ST-elevation of Ն1 mV for Ն20 minutes (not known to be preexisting or resulting from a coexisting disorder) in Ն2 contiguous leads and planned primary PCI (defined as PCI within the first 24 hours after symptom onset) or new or presumed-new left bundle-branch block (LBBB) and planned primary PCI. A sensitivity analysis also included patients with a discharge diagnosis of ST-elevation myocardial infarction (STEMI). Key exclusion criteria included contraindication to clopidogrel, fibrinolytic therapy within 24 hours before randomization, need for oral anticoagulation therapy, an index event as an acute complication of PCI or PCI performed before the first study dose, an increased risk of bradycardia (eg, known sick sinus syndrome, second-degree atrioventricular block, third-degree atrioventricular block, or previously documented syncope suspected to be due to bradycardia, all in the absence of a pacemaker), and concomitant therapy with strong CYP3A inhibitors or inducers. The study protocol was approved by an independent Ethics Committee or Institutional Review Board, and informed consent was required before any study procedure.
Events
Events definitions have been previously provided. 16, 17 MI was defined in accordance with the universal definition. 19 Stent thrombosis was evaluated according to Academic Research Consortium criteria. 20 Major life-threatening bleeding was defined as any fatal bleed, intracranial bleed, intrapericardial bleed with cardiac tamponade, or hypovolemic shock/severe hypotension caused by bleeding requiring pressors or surgery; a fall in hemoglobin of Ն50 g/L (3.1 mmol/L); or a need for transfusion of Ն4 U red cells. Other major bleeding was defined as significantly disabling bleeding, a fall in hemoglobin of Ն30 g/L but Ͻ50 g/L (Ն1.9 and Ͻ3.1 mmol/L), or a need for transfusion of 2 to 3 U red cells. PLATO-defined minor bleeding included any bleed requiring medical intervention to stop or treat. An independent blinded central adjudication committee adjudicated primary and secondary end points and bleeding events.
Statistics
The PLATO primary efficacy end point was time to first occurrence in the total cohort of any event from the composite of death from vascular causes, MI, or stroke. Other efficacy end points were the individual components of the primary end point, all-cause mortality, and different composites of death from vascular causes, MI, stroke, severe recurrent cardiac ischemia, recurrent cardiac ischemia, transient ischemic attack, or other arterial thrombotic events. Another predefined outcome was the occurrence of stent thrombosis. Safety was analyzed in the safety set, comprising patients who had taken any study medication. The primary safety end point was the time to first occurrence of any major bleeding event in the total cohort and was assessed separately in the subsets of patients undergoing CABG and/or PCI.
A Cox proportional-hazards model, with a factor for treatment group, was used to analyze the primary and secondary end points. Given the randomized design, no covariates were included in the model. All analyses were intent to treat. Because there are potential discrepancies between the admission and final diagnoses in patients with acute MI, 21 sensitivity analyses were performed to explore results consistency using different definitions of the STEMI population, in particular analyzing the group of patients with a discharge diagnosis of STEMI. The consistency of the treatment effect on the primary end point was also analyzed in subgroups based on age, gender, presence of diabetes mellitus, Thrombolysis in Myocardial Infarction (TIMI) risk score, 22 treatment with an intravenous glycoprotein IIb/IIIa blocker, time to randomization, elevated troponin at randomization, Killip class, clopidogrel before randomization and total intended clopidogrel dose up to 24 hours, type of stent, and geographic region of enrollment. Descriptive statistics are presented for each subanalysis and the variation in treatment effect (based on tests for interaction using the Cox model without adjustment of the P values for multiple comparisons). Although planned in the statistical analysis plan, neither the STE-ACS analysis nor its subsets were separately powered to detect treatment effects.
Results

Patients
The PLATO trial enrolled 18 624 patients with ACS from 862 centers in 43 countries between October 2006 and July 2008. Follow-up of the last patient ended in February 2009. Of these patients, 7544 (40.5%) fulfilled the definition for STE-ACS delineated previously ( Figure 1 ), and an additional 886 patients had STEMI documented as a discharge diagnosis. According to the investigators' interpretation of the presentation ECG, 90.5% showed STE Ն1 mm and 9.5% showed LBBB. The 2 treatment groups were balanced with regard to baseline characteristics, initial treatments, and procedures (Tables 1 and 2 ). Of note, 44% of the patients had received open-label clopidogrel before randomization. In addition, the total "intended" dose of clopidogrel (open label and blinded) given in the first 24 hours was 600 mg in 35.6% of the patients. The randomized treatment was given for a median duration of 280 days and discontinued prematurely in 19.1% and 18.4% of the patients in the ticagrelor and clopidogrel groups, respectively.
Efficacy
The primary end point occurred in 9.4% versus 10.8% of the ticagrelor and clopidogrel groups, respectively (hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.75 to 1.01; Pϭ0.07; Figure 2A ). This nominal 13% reduction was consistent with the effect of ticagrelor in the overall trial, and there was no significant interaction between the treatment effect and presence or absence of STE/LBBB at presentation (interaction Pϭ0.29). The effect of ticagrelor on the primary end point was consistent across various predefined subgroups classified according to prerandomization characteristics or postrandomization treatment use, without interaction between these and treatment effect (Figure 3 ), although the HR for ticagrelor (compared with clopidogrel) was Ͻ1 for all regions except North America (P for interactionϭ0.39). In particular, the effect of ti- 
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Ticagrelor in STE-ACS cagrelor was similar regardless of the dose of open-label clopidogrel administered before randomization and regardless of the intended total dose of clopidogrel administered during the first 24 hours (because physicians were allowed to reload patients before PCI). In the sensitivity analysis, the effect on the primary end point was similar for patients with STE at presentation, those with LBBB at presentation, and patients with a final diagnosis of STEMI (Figure 3 ). When any of these 3 criteria was used to define the STE-ACS population (nϭ8430), ticagrelor reduced the primary end point by 15% compared with clopidogrel (9.3% versus 11.0%; HR, 0.85; 95% CI, 0.74 to 0.97; Pϭ0.02).
Ticagrelor reduced the incidence of several secondary end points compared with clopidogrel, including the composite of cardiovascular death and MI, to 8.4% from 10.2% (HR, 0.82; 95% CI, 0.71 to 0.96; Pϭ0.01; Figure 2B ), the composite of all-cause mortality, MI, and stroke to 9.8% from 11.3% (HR, 0.87; 95% CI, 0.75 to 1.00; Pϭ0.05), and the composite of all arterial thrombotic events to 13.3% from 15.0% (HR, 0.87; 95% CI, 0.77 to 0.99; Pϭ0.03). Ticagrelor also reduced the incidence of MI compared with clopidogrel (4.7% versus 5.8%, respectively; Pϭ0.03). There was a nominal reduction in cardiovascular death to 4.5% from 5.5% (HR, 0.83; 95% CI, 0.67 to 1.02; Pϭ0.07) and a reduction to 5.0% from 6.1% in all-cause mortality (HR, 0.82; 95% CI, 0.67 to 1.00;
Pϭ0.05; Figure 2C and Table 3 ). The incidence of stent thrombosis was reduced by ticagrelor compared with clopidogrel, regardless of how stent thrombosis was defined (definite, definite or probable, or possible). The effects on these secondary end points were also consistent when the group of patients with STEMI as a discharge diagnosis only was added.
There was a low rate of stroke, which was higher with ticagrelor than with clopidogrel (1.7% versus 1.0%; HR, 1.63; 95% CI, 1.07 to 2.48; Pϭ0.02; Table 3 and Figure 2D) . This difference was observed consistently, although it was not statistically significant, in the sensitivity analysis adding patients with STEMI as a discharge diagnosis (1.6% versus 1.0%; HR, 1.63; 95% CI, 0.98 to 2.17; Pϭ0.07).
Safety
There was no difference between groups with regard to the primary safety end point of major bleeding (HR, 0.98; 95% CI, 0.83 to 1.14; Pϭ0.76; Figure 4 ). Using protocol definitions, there was no difference in bleeding rates between ticagrelor and clopidogrel (for fatal, life-threatening, major, major and minor, CABG-related or not related, and procedure-related or not related bleedings), except for the combination of non-procedure-related major and minor bleeding, which was more frequent with ticagrelor than with clopidogrel (5.1% versus 3.7%; HR, 1.31; 95% CI, 1.04 to 1.66; Pϭ0.02; Table 4 ). When using TIMI definitions, there was no difference in bleeding rates between the 2 trial arms. Intracerebral bleedings were very rare in both groups (0.4% versus 0.2%; HR, 1.46; 95% CI, 0.62 to 3.41; Pϭ0.38), as were fatal bleeds. The bleeding results were consistent in the sensitivity analysis adding the group of patients with a discharge diagnosis of STEMI.
Dyspnea was more frequent with ticagrelor than with clopidogrel but rarely required drug discontinuation (0.5% versus 0.1%; Pϭ0.0004). The incidence of bradycardia and syncope and the need for pacemaker were similar in the 2 groups (Table 5 ).
Discussion
These results are consistent with the PLATO overall results, 17 in which ticagrelor reduced the risk of death from vascular causes, MI, or stroke during 12 months by 16% without increasing the risk of major bleeding and without interaction with the type of clinical presentation (ie, STE-ACS or non-STE-ACS). Among patients with STE-ACS, ticagrelor produced a nominal 13% reduction in the primary end point, which appeared homogeneous across various definitions and various prespecified subgroups. The geographic interaction seen in the overall trial (with an HR Ͼ1 for North America) was no longer significant among STEMI patients but cannot be ruled out given the lower power in this subset analysis. There was no interaction between the effect of ticagrelor and the initial presentation with or without STE or LBBB (P for interactionϭ0.29). Ticagrelor produced a 1.8% absolute and an 18% relative reduction in the composite of MI and cardiovascular mortality and reduced all-cause mortality by an absolute 1.1% and a relative 18%. There was also a 1.0% absolute reduction (25% relative) in the risk of all stent thromboses and a 0.8% absolute (34% relative) reduction in definite stent thrombosis.
Treatment with ticagrelor was, however, associated with an increase in the risk of stroke from 1.0% to 1.7% (HR, 1.63; 95% CI, 1.07 to 2.48; Pϭ0.02). The overall rate of stroke and the trend toward a higher rate with ticagrelor are consistent with the overall trial results. However, there was no increase in intracranial bleeding, and despite the increased risk of stroke, there was a noteworthy 1.1% absolute reduction in mortality. In the STE-ACS cohort, ticagrelor did not significantly increase major bleeding, regardless of the definition used (either the PLATO or the TIMI definition) and regardless of whether CABG-related or procedural bleeds were included or not. All types of bleeding seemed slightly less frequent in the STE-ACS population than in the overall trial population, despite more frequent use of percutaneous interventions and intravenous glycoprotein IIb/IIIa blockers in this population. This finding may be related to the younger age of the STE-ACS population (on average, 3 years younger than the participants in the overall trial). Similar observations were made in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38. 23 Patients with STE-ACS pose special challenges. These high-risk patients must undergo PCI as rapidly as possible after first medical contact; oral antiplatelet agents barely have time to be effective by the time the procedure is performed and are often given after the procedure is completed. 24 In PLATO, randomization was performed before angiography or PCI, and patients received study drug loading before PCI. In addition, 44% of the patients had received open-label clopidogrel before randomization, and 35.6% of patients received a clopidogrel loading dose of at least 600 mg, thereby providing opportunities for clopidogrel to reach an optimal clinical effect. Yet, the effects of ticagrelor were consistently superior regardless of the dose and timing of clopidogrel. Whether combining a double loading dose with a double maintenance dose of clopidogrel might have improved outcomes in the clopidogrel group is unknown. However, this dosing strategy did not improve survival compared with standard dosing in the Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events-Seventh Organization to Assess Strategies in Ischemic Syndromes (CURRENT-OASIS7) trial. 25 Ticagrelor has been associated with side effects such as bradycardia and dyspnea, postulated to relate to blockage by ticagrelor of adenosine reuptake by red blood cells. 26 In the STE-ACS population, there was a modest excess of "any dyspnea," but the frequency of dyspnea requiring treatment discontinuation, although more frequent with ticagrelor, was very low in both groups (0.5% versus 0.1%; Pϭ0.0003), even though dyspnea, heart failure, and previous history of pulmonary disease or heart failure in any form were not exclusion criteria. Likewise, despite concern about possible ticagrelorinduced bradycardia in the context of STE-ACS, there was no excess of investigator-reported bradycardia or associated events.
There are limitations to this subgroup analysis of a randomized trial. Although outcomes in the STE-ACS subgroup were generally consistent with those of the overall trial, nominal statistical significance was not reached for all end points and varied according to the definition used. The population of STE-ACS patients in this trial was recruited as soon as possible after entry to hospital and therefore was somewhat heterogeneous, including patients presenting with STE or LBBB and patients with a discharge diagnosis of STEMI. Treatment was also heterogeneous, including patients with and without clopidogrel pretreatment and various loading doses of blinded clopidogrel or placebo, as well as some patients who eventually did not undergo primary PCI. However, the effects of ticagrelor versus clopidogrel on major efficacy and safety end points were consistent regardless of the STEMI definition, patient characteristics, and adjunctive clopidogrel dose given before or after randomization. The reduction in secondary efficacy end points appeared to accrue over time, and the event curves suggested that the bulk of the clinical benefit was obtained during long-term treatment. However, this result might be influenced by the stringent criteria used to diagnose reinfarction in patients with developing STEMI and rising biomarker levels at entry in whom no reinfarctions may be diagnosed according to the current diagnosis definitions. 19 This may have led to an underestimation of its incidence in the initial phase and thus reduced the power to detect an early benefit.
Conclusions
In patients with STE-ACS intended for reperfusion with primary PCI, the effects of ticagrelor compared with clopidogrel were consistent with those seen in the overall PLATO trial. Ticagrelor produced a consistent reduction in cardiovascular and total death, MI, and stent thrombosis and improved survival without increasing major bleeding but with a higher rate of stroke. The absolute mortality reduction from ticagrelor over clopidogrel is of the same magnitude as that achieved with tissue plasminogen activator compared with streptokinase 27 but without the corresponding increase in intracranial bleeding and with a reduction in reinfarction not seen with thrombolysis. Furthermore, these benefits are obtained compared with active treatment with clopidogrel and on top of aspirin, primary PCI, and other evidence-based secondary prevention therapies widely used in PLATO patients. 
